OncoMatch/Clinical Trials/NCT05768919
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Is NCT05768919 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Treatment Period 1 and Treatment Period 2 for glioblastoma.
Treatment: Treatment Period 1 · Treatment Period 2 · Treatment Period 3 · Treatment Period 4a — The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Allowed: MGMT methylated promoter
Patients with methylated or unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) promoter are eligible
Allowed: MGMT unmethylated promoter
Patients with methylated or unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) promoter are eligible
Allowed: IDH1 wild-type
IDH WT and mutant patients as long as the treatment plan is for combined XRT/TMZ
Allowed: IDH1 mutation
IDH WT and mutant patients as long as the treatment plan is for combined XRT/TMZ
Lab requirements
Blood counts
Hgb > 9 g/dL; ANC ≥ 1500/µL; Platelet count ≥ 100,000/µL
Kidney function
eGFR ≥ 60 mL/min/1.73 m2 unless data exist supporting safe use at lower values of renal function, but eGFR must be ≥ 30 mL/min/1.73 m2
Liver function
Total bilirubin ≤ 1.5 × institutional ULN; AST and ALT ≤ 3 × institutional ULN
Adequate organ and marrow function defined as: Hgb > 9 g/dL; ANC ≥ 1500/µL; Platelet count ≥ 100,000/µL; Total bilirubin ≤ 1.5 × institutional ULN; AST and ALT ≤ 3 × institutional ULN OR eGFR ≥ 60 mL/min/1.73 m2 unless data exist supporting safe use at lower values of renal function, but eGFR must be ≥ 30 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sibley Memorial Hospital · Washington D.C., District of Columbia
- Johns Hopkins University/Johns Hopkins Hospital · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify